Compare Regeneron Pharmaceuticals Inc (REGN) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs VICI Properties Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while VICI Properties Inc trades at $26.61 (market cap $29.27B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.4× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.77%). Which is the better fit depends on your goals.
| REGN | VICI | |
|---|---|---|
Market Cap | $70.79B | $29.27B |
Sector | Health | Real Estate |
52-Week High | $812.27 | $33.93 |
52-Week Low | $545.46 | $25.94 |
Enterprise Value | $64.74B | $46.49B |
Dividend Yield | 0.56% | 6.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VICI Properties trades at $26.83, down slightly (-0.15%) on the day. The stock shows strong fundamentals with a P/E of 9.19, net income margin of 76.83%, and consistent earnings beats in recent quarters. Technical indicators are mixed with an overall bullish signal but bearish moving averages. Recent news highlights institutional activity with CalPERS reducing its stake while Aviance Capital Partners initiated a new position.
VICI offers a compelling investment case with attractive valuation metrics, robust profitability, and a 6.62% dividend yield. However, risks include tenant concentration with Caesars/MGM accounting for 70% of rent and potential lease uncertainties from recent buyout discussions. Analyst consensus remains strongly bullish with a $29.00 price target suggesting 8% upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
